NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney DiseaseYou must be logged in to view this page.
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)You must be logged in to view this page.
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.You must be logged in to view this page.
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic RetinopathyYou must be logged in to view this page.
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis StudyYou must be logged in to view this page.
Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 YearYou must be logged in to view this page.
AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory DiseasesYou must be logged in to view this page.
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transferYou must be logged in to view this page.
Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated DiseasesYou must be logged in to view this page.
VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trialYou must be logged in to view this page.
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative DiseasesYou must be logged in to view this page.